— Published Date: 12/20/2024
Value Proposition: Treats brain tumors by combining a hematopoietic growth protein and cancer therapeutics to increase survival rates.
Technology Description
Researchers at Washington University in St. Louis have developed a new way to treat brain cancers by combining…
— Value Proposition: This invention targets MXRA8 protein as a therapy for obesity and other metabolic diseases.
Technology Description
Researchers at Washington University in St. Louis have developed an MXRA8 targeted therapeutic to treat obesity and associated metabolic diseases. MXRA8 is the re…
— VLDLR-based Decoy Receptors to Prevent Alphavirus Infections
Technology Description
Researchers at Washington University in St. Louis have developed very low-density lipoprotein receptor (VLDLR) soluble decoy receptors with potent inhibitory activity in vitro and in vivo. Eastern equine encephali…
— T-017429 Engineered Oncolytic Zika Virus Therapy for Glioblastoma
Technology Description
Researchers in the laboratories of Michael Diamond and Milan Chheda at Washington University have developed prospective treatments for glioblastoma (GBM) through the application of an engineered Zika virus (ZI…
— Disease indication – SARS-CoV-2 infection (COVID-19)
Drug format – Chimeric monoclonal antibody
Drug class – Best-in-class
Research stage and Preliminary data – The inventors have developed and characterized this antibody, creating a chimeric version with a human IgG backbone. T…
— Disease indication – Venezuelan equine encephalitis virus (VEEV) infection, either naturally-arising and as a result of bioterrorism
Drug format – Biologic (soluble receptor fusion protein)
Drug class – First-in-class
Mode of action – This soluble fusion protein contains domain …
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
